Signaling of prostaglandin e receptors, EP3 and EP4 facilitates wound healing and lymphangiogenesis with enhanced recruitment of M2 macrophages in mice

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Hosono, Kanako ^a,b   Isonaka, Risa ^b   Kawakami, Tadashi ^b   Narumiya, Shuh ^c   Majima, Masataka ^a,b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE 1; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; CD11B ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E SYNTHASE; PTGES PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GRANULATION TISSUE; LYMPHANGIOGENESIS; LYVE 1 GENE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VEGFR 3 GENE; WOUND HEALING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; EAR; GENE INACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD11B; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EAR; GENE KNOCKOUT TECHNIQUES; LYMPHANGIOGENESIS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PROSTAGLANDIN-E SYNTHASES; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; WOUND HEALING;

EID: 84990876720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162532     Document Type: Article

References (53)

1. Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends in immunology. 2012; 33(7):350-6. Epub 2012/05/15. doi: 10.1016/j.it.2012.03.006 PMID: 22579522.
2. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. The American journal of pathology. 2000; 156(5):1499-504. Epub 2000/05/04. doi: 10.1016/s0002-9440(10)65021-3 PMID: 10793061; PubMed Central PMCID: PMCPMC1876915.
3. Kurashige C, Hosono K, Matsuda H, Tsujikawa K, Okamoto H, Majima M. Roles of receptor activitymodifying protein 1 in angiogenesis and lymphangiogenesis during skin wound healing in mice. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014; 28(3):1237-47. Epub 2013/12/07. doi: 10.1096/fj.13-238998 PMID: 24308973.
4. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. The Journal of clinical investigation. 2005; 115(2):247-57. Epub 2005/01/26. doi: 10.1172/jci22037 PMID: 15668734; PubMed Central PMCID: PMCPMC544601.
5. Yao LC, McDonald DM. Plasticity of airway lymphatics in development and disease. Advances in anatomy, embryology, and cell biology. 2014; 214:41-54. Epub 2013/11/28. doi: 10.1007/978-3-7091-1646-3-4 PMID: 24276885; PubMed Central PMCID: PMCPMC3955364.
6. Kaiserling E, Krober S, Geleff S. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology. 2003; 36(2):52-61. Epub 2003/08/21. PMID: 12926829.
7. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006; 130(7):2060-73. Epub 2006/06/10. doi: 10.1053/j.gastro.2006.03.054 PMID: 16762629.
8. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflammatory bowel diseases. 2013; 19(9):1983-9. Epub 2013/07/10. doi: 10.1097/MIB.0b013e31829292f7 PMID: 23835443; PubMed Central PMCID: PMCPMC3732464.
9. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. The Journal of experimental medicine. 2005; 201(7):1089-99. Epub 2005/04/06. doi: 10.1084/jem.20041896 PMID: 15809353; PubMed Central PMCID: PMCPMC2213132.
10. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annual review of pathology. 2008; 3:367-97. Epub 2007/11/28. doi: 10.1146/annurev.pathmechdis.3.121806.151515 PMID: 18039141.
11. Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. Journal of cellular and molecular medicine. 2009; 13(8A):1405-16. Epub 2009/07/09. doi: 10.1111/j.1582-4934.2009.00834.x PMID: 19583813; PubMed Central PMCID: PMCPMC3572232.
12. Guo R, Zhou Q, Proulx ST, Wood R, Ji RC, Ritchlin CT, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis and rheumatism. 2009; 60 (9):2666-76. Epub 2009/08/29. doi: 10.1002/art.24764 PMID: 19714652; PubMed Central PMCID: PMCPMC2810533.
13. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature immunology. 2004; 5(1):74-80. Epub 2003/11/25. doi: 10.1038/ni1013 PMID: 14634646.
14. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010; 140(4):460-76. Epub 2010/02/25. doi: 10.1016/j.cell.2010.01.045 PMID: 20178740.
15. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circulation research. 2003; 92(10):1098-106. Epub 2003/04/26. doi: 10.1161/01.res. 0000073584.46059.e3 PMID: 12714562.
16. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. The Journal of biological chemistry. 2001; 276(22):19166-71. Epub 2001/03/30. doi: 10.1074/jbc.M100097200 PMID: 11279005.
17. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005; 438(7070):946-53. Epub 2005/12/16. doi: 10.1038/nature04480 PMID: 16355212.
18. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. The Journal of biological chemistry. 1998; 273(14):8413-8. Epub 1998/05/09. doi: 10.1074/jbc.273.14.8413 PMID: 9525952.
19. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. The Journal of clinical investigation. 2005; 115(9):2363-72. Epub 2005/09/03. doi: 10.1172/jci23874 PMID: 16138190; PubMed Central PMCID: PMCPMC1193872.
20. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. The Journal of clinical investigation. 2005; 115(9):2316-9. Epub 2005/09/03. doi: 10.1172/jci26354 PMID: 16138185; PubMed Central PMCID: PMCPMC1193892.
21. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. British journal of pharmacology. 2000; 130(3):641-9. Epub 2000/05/24. doi: 10.1038/sj.bjp.0703327 PMID: 10821793; PubMed Central PMCID: PMCPMC1572093.
22. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. The Journal of experimental medicine. 2003; 197(2):221-32. Epub 2003/01/23. doi: 10.1084/jem.20021408 PMID: 12538661; PubMed Central PMCID: PMCPMC2193807.
23. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends in pharmacological sciences. 2003; 24(10):524-9. Epub 2003/10/16. doi: 10.1016/j.tips. 2003.08.005 PMID: 14559404.
24. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. The American journal of pathology. 2010; 176(3):1469-83. Epub 2010/01/30. doi: 10.2353/ ajpath.2010.090607 PMID: 20110411; PubMed Central PMCID: PMCPMC2832166.
25. Ae T, Ohno T, Hattori Y, Suzuki T, Hosono K, Minamino T, et al. Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers. American journal of physiology Gastrointestinal and liver physiology. 2010; 299(5):G1139-46. Epub 2010/09/04. doi: 10. 1152/ajpgi.00013.2010 PMID: 20813913.
26. Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E, Majima M. Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema. Laboratory investigation; a journal of technical methods and pathology. 2011; 91(9):1314-25. Epub 2011/05/18. doi: 10.1038/ labinvest.2011.84 PMID: 21577211.
27. Kubo H, Hosono K, Suzuki T, Ogawa Y, Kato H, Kamata H, et al. Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2010; 64(2):101-6. Epub 2009/12/26. doi: 10.1016/j.biopha.2009.04.039 PMID: 20034758.
28. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochemical and biophysical research communications. 1998; 246(1):7-12. Epub 1998/05/26. doi: 10.1006/bbrc.1998.8461 PMID: 9600059.
29. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature. 1998; 395(6699):281-4. doi: 10. 1038/26233 PMID: 9751056.
30. Oike Y, Yasunaga K, Ito Y, Matsumoto S, Maekawa H, Morisada T, et al. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(16):9494-9. Epub 2003/07/23 doi: 10.1073/pnas.1531901100 PMID: 12871997; PubMed Central PMCID: PMCPMC170946.
31. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, et al. VEGFR-3 in adult angiogenesis. The Journal of pathology. 2001; 195(4):490-7. Epub 2001/12/18. doi: 10.1002/path.969 PMID: 11745682.
32. Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, et al. Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circulation research. 2007; 100(4):e47-57. Epub 2007/02/03. doi: 10. 1161/01.res.0000259564.92792.93 PMID: 17272806.
33. Yin N, Zhang N, Lal G, Xu J, Yan M, Ding Y, et al. Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PloS one. 2011; 6(11):e28023. Epub 2011/12/02. doi: 10.1371/journal. pone.0028023 PMID: 22132197; PubMed Central PMCID: PMCPMC3223214.
34. Hirai S, Naito M, Terayama H, Qu N, Kuerban M, Musha M, et al. Lymphangiogenesis in chronic inflammation in the testis. Andrology. 2013; 1(1):147-54. Epub 2012/12/22. doi: 10.1111/j.2047-2927. 2012.00015.x PMID: 23258644.
35. Zheng M, Kimura S, Nio-Kobayashi J, Takahashi-Iwanaga H, Iwanaga T. Three types of macrophagic cells in the mesentery of mice with special reference to LYVE-1-immunoreactive cells. Biomedical research (Tokyo, Japan). 2014; 35(1):37-45. Epub 2014/02/28. PMID: 24573200.
36. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflammation research: official journal of the European Histamine Research Society [et al]. 2000; 49(8):367-92. Epub 2000/10/12. doi: 10.1007/s000110050605 PMID: 11028754.
37. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annual review of physiology. 2001; 63:579-605. Epub 2001/02/22. doi: 10.1146/annurev.physiol.63.1.579 PMID: 11181968.
38. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochimica et biophysica acta. 2000; 1483(2):285-93. Epub 2000/01/15. doi: 10.1016/S1388-1981 (99)00164-X PMID: 10634944.
39. Funk CD, Furci L, FitzGerald GA, Grygorczyk R, Rochette C, Bayne MA, et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. The Journal of biological chemistry. 1993; 268(35):26767-72. Epub 1993/12/15. PMID: 8253813.
40. Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, et al. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. The Journal of biological chemistry. 1993; 268 (27):20175-8. Epub 1993/09/25. PMID: 7690750.
41. Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. The Journal of biological chemistry. 1993; 268 (11):7759-62. Epub 1993/04/15. PMID: 8385118.
42. Woodward DF, Pepperl DJ, Burkey TH, Regan JW. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochemical pharmacology. 1995; 50(10):1731-3. Epub 1995/11/09. doi: 10.1016/0006-2952(95)02035-7 PMID: 7503778.
43. Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. The Journal of biological chemistry. 1992; 267 (10):6463-6. Epub 1992/04/05. PMID: 1372606.
44. Irie A, Sugimoto Y, Namba T, Harazono A, Honda A, Watabe A, et al. Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. European journal of biochemistry / FEBS. 1993; 217(1):313-8. Epub 1993/10/01. doi: 10.1111/j.1432-1033.1993.tb18248.x PMID: 8223569.
45. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature. 1993; 365 (6442):166-70. Epub 1993/09/09. doi: 10.1038/365166a0 PMID: 8396726.
46. Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. Journal of biochemistry. 2002; 131(6):781-4. Epub 2002/06/01. doi: 10.1093/oxfordjournals. jbchem.a003165 PMID: 12038972.
47. Brancato SK, Albina JE. Wound macrophages as key regulators of repair: origin, phenotype, and function. The American journal of pathology. 2011; 178(1):19-25. Epub 2011/01/13. doi: 10.1016/j.ajpath. 2010.08.003 PMID: 21224038; PubMed Central PMCID: PMCPMC3069845.
48. Ji RC. Macrophages are important mediators of either tumor-or inflammation-induced lymphangiogenesis. Cellular and molecular life sciences: CMLS. 2012; 69(6):897-914. Epub 2011/10/11. doi: 10. 1007/s00018-011-0848-6 PMID: 21984600.
49. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. The Journal of pathology. 2006; 209 (1):67-77. Epub 2006/02/17. doi: 10.1002/path.1942 PMID: 16482496.
50. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. The Journal of clinical investigation. 2004; 113(7):1040-50. Epub 2004/04/02. doi: 10.1172/ jci20465 PMID: 15057311; PubMed Central PMCID: PMCPMC379325.
51. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nature medicine. 2009; 15(5):545-52. Epub 2009/05/05. doi: 10.1038/nm.1960 PMID: 19412173.
52. Zhang MZ, Yao B, Wang Y, Yang S, Wang S, Fan X, et al. Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension. The Journal of clinical investigation. 2015; 125 (11):4281-94. Epub 2015/10/21. doi: 10.1172/jci81550 PMID: 26485285; PubMed Central PMCID: PMCPMC4639986.
53. Binger KJ, Gebhardt M, Heinig M, Rintisch C, Schroeder A, Neuhofer W, et al. High salt reduces the activation of IL-4-and IL-13-stimulated macrophages. The Journal of clinical investigation. 2015; 125 (11):4223-38. Epub 2015/10/21. doi: 10.1172/jci80919 PMID: 26485286; PubMed Central PMCID: PMCPMC4639967.